DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic target
International Journal of Cancer · 01.06.2025 · 156 (11) · 2068-2086
DOI: 10.1002/ijc.35365 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 08.03.2025. Verfasst von Ahmad Ghorbani Vanan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Gastrointestinal Neoplasms, Protein Serine-Threonine Kinases, Intracellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 117 Literaturangaben.
Abstract (Originalsprache)
Cancers of the gastrointestinal (GI) tract, including colorectal, pancreatic, and hepatocellular carcinomas, represent a significant global health burden due to their high incidence and mortality rates. Doublecortin‐like kinase 1 (DCLK1), initially identified for its role in neurogenesis, has emerged as a crucial player in GI cancer progression. This review comprehensively examines the multifaceted roles of DCLK1 in GI cancers, focusing on its structural isoforms, functions in normal and inflammatory states, and contributions to cancer progression and metastasis. DCLK1 is overexpressed in various GI cancers and is associated with poor prognosis, enhanced tumorigenic potential, and increased metastatic capacity. The review discusses the molecular mechanisms through which DCLK1 influences cancer stem cell maintenance, epithelial‐mesenchymal transition (EMT), and cell survival pathways, as well as its interactions with key signaling pathways such as Notch, WNT/β‐catenin, and NF‐κB. The potential of DCLK1 as a therapeutic target is also explored, highlighting preclinical and early clinical efforts to inhibit its function using small molecule inhibitors or monoclonal antibodies. Despite significant advancements, further research is needed to fully elucidate DCLK1's role in GI cancers and to develop effective therapeutic strategies targeting this protein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Molecular Genetics, Faculty of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran.
- Department of Medicine, Tehran Medical Branch, Islamic Azad University, Tehran, Iran.
- Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
- Toxicological Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.
ORCID-Profile: Safa Tahmasebi
Zitieren
APA
Vanan, A. G., Vesal, S., Seraj, P., Ghezel, M. A., Eini, P., Talebileili, M., Asgari, Z., Tahmasebi, S., Hashemi, M., & Taheriazam, A. (2025). DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic target. International Journal of Cancer, 156(11), 2068-2086. https://doi.org/10.1002/ijc.35365
Vancouver
Vanan AG, Vesal S, Seraj P, Ghezel MA, Eini P, Talebileili M, et al. DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic target. International Journal of Cancer. 2025;156(11):2068-2086. doi:10.1002/ijc.35365
BibTeX
@article{Vanan2025,
author = {Vanan, Ahmad Ghorbani and Vesal, Soheil and Seraj, Parmida and Ghezel, Mohammad Amin and Eini, Pooya and Talebileili, Maryam and Asgari, Zeynab and Tahmasebi, Safa and Hashemi, Mehrdad and Taheriazam, Afshin},
title = {DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic target},
journal = {International Journal of Cancer},
year = {2025},
volume = {156},
number = {11},
pages = {2068--2086},
doi = {10.1002/ijc.35365}
}
EUVIMED